Vidac Pharma is at the forefront of developing innovative anti-cancer therapies through its unique approach to targeting the Warburg effect, a metabolic alteration commonly seen in cancer cells. The company focuses on its proprietary Novel Chemical Entities (VDA-NCEs), which work by disrupting the anchoring of the Hexokinase-2 (HK2) enzyme to voltage-dependent anion channels (VDAC) in the mitochondria. This disruption allows for a reversal of the cancer cell's altered metabolism, inhibiting tumor growth, reactivating immune responses, and ultimately halting cancer proliferation. By addressing the metabolic processes that support tumor survival, Vidac Pharma aims to create effective treatments for various oncologic and onco-dermatologic diseases.

The company's lead drug candidate, VDA-1102, specifically targets advanced Actinic Keratosis (AK) and Cutaneous T-cell Lymphoma (CTCL), showcasing Vidac's commitment to developing first-in-class anti-cancer drugs. The mechanism of action, referred to as the "toposteric effect," allows Vidac's compounds to prevent HK2 from blocking mitochondrial channels without completely inhibiting glycolysis, thus preserving normal cellular functions. This innovative strategy has shown promising results in early clinical trials, indicating the potential for Vidac Pharma's therapies to provide new avenues for cancer treatment while minimizing harm to healthy tissues.

Israel

Vidac is a clinical stage innovative biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncology and dermatology ailments. We at Vidac are passionate about transforming breakthrough science into innovative therapies to address major unmet medical needs.
Our breakthrough technology targets the VDAC/HK2 system that is unique to malignant cells. Modulating this target leads to selective apoptosis of cancer cells without affecting the surrounding healthy tissue, thus holds the promise of delivering first-in-class drugs that are both efficacious and well tolerated by patients.

Vidac Pharma

Company Details